CO6230992A2 - Aril fosforamidatos de nucleosido y su uso como agentes antivirales para el tratamiento del virus de la hepatitis c - Google Patents

Aril fosforamidatos de nucleosido y su uso como agentes antivirales para el tratamiento del virus de la hepatitis c

Info

Publication number
CO6230992A2
CO6230992A2 CO09064160A CO09064160A CO6230992A2 CO 6230992 A2 CO6230992 A2 CO 6230992A2 CO 09064160 A CO09064160 A CO 09064160A CO 09064160 A CO09064160 A CO 09064160A CO 6230992 A2 CO6230992 A2 CO 6230992A2
Authority
CO
Colombia
Prior art keywords
nucleoside
hepatitis
virus
treatment
aril
Prior art date
Application number
CO09064160A
Other languages
English (en)
Inventor
Christopher Mccguigan
Plinio Perrone
Johan Neyts
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff filed Critical Univ Cardiff
Publication of CO6230992A2 publication Critical patent/CO6230992A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

1.- Un compuesto de fórmula I:en donde: Ar comprende dos o más anillos aromáticos fusionados y se seleccionan del grupo que consiste de arilo(C9-30) y heteroarilo (C6-30) cualquiera de tales anillos están sustituidos opcionalmente; T se selecciona del grupo que consiste de hidrógeno (-H), fluor (-F), azido (-N3), amino (-NH2), hidroxilo (-OH), alquilo (C1-3) (C1-3-) , alcoxilo (C1-3O-) mercapto (-SH) y alquiltio (C1-3) (C1-3S-); V es seleccionado del grupo que consiste de -OT', hidrógeno (-H), fluor (-F) y cloro (-Cl), en donde T' es seleccionado del grupo que consiste de hidrógeno (-H), metilo (-CH3), alquil(C1-16)carbonilo (alquil(C1-16)-C(=O)-), alquenil(C2-18) carbonilo (alquenil(C2-18)-C(=O)-), alcoxi (C1-10)carbonilo(alquil (C1-10)-O-C(=O)-), cicloalquil(C3-6)carbonilo (cicloalquil(C3-6)-C(=O)-), cicloalquiloxy(C3-6)carbonilo(cicloalquil (C3-6)-O-C(=O)-);T" es seleccionado del grupo que consiste de hidrógeno (-H), metilo (-CH3), alquil (C1-16) carbonilo (alquil (C1-16)-C(=O)-), alquenil(C2-18)carbonilo (alquenil(C2-18)-C(=O)-), alquiloxi(C1-10) carbonilo (alquil(C1-10)-O-C(=O)-), cicloalquil (C3-6)carbonilo (cicloalquil(C3-6)-C(=O)-), cicloalquiloxy(C3- 6) carbonilo (cicloalquil (C3-6)-O-C(=O)-);n es 0 ó 1. en donde cuando n es 1, X es =O, y cuando n es 0, un enlace doble existe entre la posición 3 y la posición 4 y X es seleccionado del grupo que consiste de H, OH, F, Cl, Br, I, alquilo(C1-6) y NR5R6, en donde cada uno de R5 y R6 es seleccionado independientemente entre H y alquilo(C1-6); Z es seleccionado del grupo que consiste de H, OH, F, Cl, Br, I, alquilo (C1-6) y NR5R6, en donde cada uno de R5 y R6 es seleccionado independientemente entre H y alquilo (C1-6); Y es seleccionado del grupo que consiste de H, OH, F, Cl, Br, I, alquilo(C1-6), alquinilo(C2-8) y NR5R6, en donde cada uno de R5 y R6 es seleccionado independientemente entre H y alquilo (C1-6); Q es seleccionado del grupo que consiste de O, S y CR7R8, ...
CO09064160A 2006-11-24 2009-06-19 Aril fosforamidatos de nucleosido y su uso como agentes antivirales para el tratamiento del virus de la hepatitis c CO6230992A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0623493.4A GB0623493D0 (en) 2006-11-24 2006-11-24 Chemical compounds

Publications (1)

Publication Number Publication Date
CO6230992A2 true CO6230992A2 (es) 2010-12-20

Family

ID=37636469

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09064160A CO6230992A2 (es) 2006-11-24 2009-06-19 Aril fosforamidatos de nucleosido y su uso como agentes antivirales para el tratamiento del virus de la hepatitis c

Country Status (26)

Country Link
US (1) US8658616B2 (es)
EP (2) EP2412717A1 (es)
JP (1) JP5271913B2 (es)
KR (1) KR20090114356A (es)
CN (1) CN101547932B (es)
AT (1) ATE512973T1 (es)
AU (1) AU2007323220B2 (es)
CA (1) CA2670328C (es)
CO (1) CO6230992A2 (es)
CY (1) CY1112254T1 (es)
DK (1) DK2097434T3 (es)
EC (1) ECSP099462A (es)
ES (1) ES2368012T3 (es)
GB (1) GB0623493D0 (es)
IL (1) IL198610A (es)
MX (1) MX2009005120A (es)
MY (1) MY145856A (es)
NO (1) NO20092399L (es)
NZ (2) NZ577152A (es)
PL (1) PL2097434T3 (es)
PT (1) PT2097434E (es)
RU (1) RU2464272C2 (es)
SG (1) SG171596A1 (es)
SI (1) SI2097434T1 (es)
WO (1) WO2008062206A2 (es)
ZA (1) ZA200904031B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201004632A (en) * 2008-07-02 2010-02-01 Idenix Pharmaceuticals Inc Compounds and pharmaceutical compositions for the treatment of viral infections
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
CA2748034A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
EA201170915A1 (ru) * 2009-01-09 2012-02-28 Юниверсити Колледж Оф Кардифф Консалтентс Лимитед Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
SG184323A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
KR20130110170A (ko) * 2010-09-22 2013-10-08 앨리오스 바이오파마 인크. 치환된 뉴클레오타이드 유사체
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
PE20150132A1 (es) 2012-05-22 2015-02-14 Idenix Pharmaceuticals Inc Compuestos d-aminoacidos para enfermedad hepatica
CA2871547C (en) 2012-05-25 2021-05-25 Janssen R&D Ireland Uracyl spirooxetane nucleosides
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
AP2015008384A0 (en) 2012-10-08 2015-04-30 Univ Montpellier Ct Nat De La Rech Scient 2'-Chloro nucleoside analogs for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
HUE044605T2 (hu) * 2012-11-16 2019-11-28 Univ College Cardiff Consultants Ltd RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
AU2014250764A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Deuterated nucleoside prodrugs useful for treating HCV
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
CN104447923B (zh) * 2013-09-23 2018-03-30 中国药科大学 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
MX2020010375A (es) 2014-11-28 2022-07-19 NuCana plc Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
UA124966C2 (uk) 2015-03-06 2021-12-22 Атеа Фармасеутікалс, Інк. <font face="Symbol">b</font>-D-2'-ДЕЗОКСИ-2'-<font face="Symbol">a</font>-ФТОР-2'-<font face="Symbol">b</font>-C-ЗАМІЩЕНІ-2-МОДИФІКОВАНІ-N<sup>6</sup>-ЗАМІЩЕНІ ПУРИНОВІ НУКЛЕОТИДИ ДЛЯ ЛІКУВАННЯ ВИКЛИКАНИХ HCV ЗАХВОРЮВАНЬ
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
AU2017324939B2 (en) 2016-09-07 2021-10-14 Atea Pharmaceuticals, Inc. 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment
IL295609B2 (en) 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614504A (en) 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
CA2675757C (en) 1995-04-21 2011-03-15 University Of South Florida Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof
WO1997021452A2 (en) 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs
US5959100A (en) 1996-03-27 1999-09-28 Nexstar Pharmaceuticals, Inc. Pyrimidine nucleosides as therapeutic and diagnostic agents
US6475985B1 (en) 1998-03-27 2002-11-05 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
US7144874B2 (en) 2002-10-25 2006-12-05 Parker Hughes Institute Aryl phosphate derivatives of d4T having activity against resistant HIV strains
US6030957A (en) 1998-06-29 2000-02-29 Wayne Hughes Institute Aryl phosphate derivatives of d4T having anti-HIV activity
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
US6620796B1 (en) 1999-11-08 2003-09-16 Micrologix Biotech Inc. Combinatorial library synthesis and pharmaceutically active compounds produced thereby
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP2004513070A (ja) 2000-05-26 2004-04-30 イデニクス（ケイマン）リミテツド β−Ｌ−２’−デオキシヌクレオシドを用いたデルタ型肝炎ウイルス感染の処置方法
CN1315862C (zh) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
US6998484B2 (en) 2000-10-04 2006-02-14 Santaris Pharma A/S Synthesis of purine locked nucleic acid analogues
MY141789A (en) * 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
EP1707571B1 (en) 2001-01-22 2011-09-28 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
WO2003000713A1 (en) 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
US7105527B2 (en) 2001-12-14 2006-09-12 Otto Michael J N4-acylcytosine nucleosides for treatment of viral infections
WO2003051899A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
US20070032448A1 (en) 2002-01-17 2007-02-08 Zhi Hong Sugar modified nucleosides as viral replication inhibitors
WO2003061385A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
JP2005522443A (ja) 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
CN1863538A (zh) * 2002-09-30 2006-11-15 健亚生物科技公司 用于治疗c型肝炎病毒感染的核苷衍生物
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
US20070265222A1 (en) 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
US7261853B2 (en) * 2004-07-16 2007-08-28 Eagle Mold Company Decelerated ejector pin system and method for operating the same
AU2005317081A1 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
US8399428B2 (en) 2004-12-09 2013-03-19 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2006116557A1 (en) * 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006121820A1 (en) * 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
EP1928475B1 (en) 2005-08-15 2018-05-23 Riboscience LLC Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
AU2007215114A1 (en) 2006-02-14 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
EP2120565B1 (en) 2006-12-20 2012-11-28 Merck Sharp & Dohme Corp. Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
EP2124555B1 (en) 2007-01-05 2015-07-08 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2008104408A2 (en) 2007-02-27 2008-09-04 K. U. Leuven Research & Development Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs

Also Published As

Publication number Publication date
US8658616B2 (en) 2014-02-25
US20110124592A1 (en) 2011-05-26
EP2412717A1 (en) 2012-02-01
ATE512973T1 (de) 2011-07-15
ES2368012T3 (es) 2011-11-11
WO2008062206A3 (en) 2008-07-10
KR20090114356A (ko) 2009-11-03
EP2097434A2 (en) 2009-09-09
NZ593712A (en) 2012-09-28
CN101547932A (zh) 2009-09-30
IL198610A (en) 2013-11-28
EP2097434B1 (en) 2011-06-15
ZA200904031B (en) 2010-04-28
MX2009005120A (es) 2009-09-23
PL2097434T3 (pl) 2011-11-30
CA2670328C (en) 2013-09-24
AU2007323220B2 (en) 2012-09-06
GB0623493D0 (en) 2007-01-03
SG171596A1 (en) 2011-06-29
JP2010510301A (ja) 2010-04-02
WO2008062206A8 (en) 2011-11-10
PT2097434E (pt) 2011-09-07
SI2097434T1 (sl) 2011-10-28
CA2670328A1 (en) 2008-05-29
JP5271913B2 (ja) 2013-08-21
DK2097434T3 (da) 2011-08-29
CY1112254T1 (el) 2015-12-09
NO20092399L (no) 2009-06-24
MY145856A (en) 2012-04-30
NZ577152A (en) 2012-01-12
RU2464272C2 (ru) 2012-10-20
CN101547932B (zh) 2014-04-16
AU2007323220A1 (en) 2008-05-29
WO2008062206A2 (en) 2008-05-29
IL198610A0 (en) 2010-02-17
RU2009123104A (ru) 2010-12-27
ECSP099462A (es) 2009-08-28

Similar Documents

Publication Publication Date Title
ECSP099462A (es) Aril fosforamidatos de nucleosido y su uso como agentes antivirales para el tratamiento del virus de la hepatitis c
NZ597544A (en) Modified 4&#39;-nucleosides as antiviral agents
NI201300107A (es) Derivados de nucleósidos 2&#39; - sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales.
EA201500304A1 (ru) Аналоги 2&#39;-хлоро нуклеозидов для инфекции вгс
UY28084A1 (es) Derivados antivirales de nucleosidos
AR082068A2 (es) Analogos de nucleosidos fluorados modificados
TW200630344A (en) Tetracyclic indole derivatives as antiviral agents
AR056850A1 (es) MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2&#39;,3&#39;-DIDEHIDRO-2&#39;,3&#39; DIDEOXI-5-FLUOROCITIDINA
MX2009012433A (es) Azido nucleosidos de purina para el tratamiento de infecciones virales.
ECSP034897A (es) Nucleosidos 4&#39;-sustituidos
ES2322602T3 (es) Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc.
CO6321235A2 (es) Analogos de carba-nucleosidos 1 sustituidos para el tratamiento antiviral
PE20160120A1 (es) Derivados de nucleosido 4&#39;-fluoro-2&#39;-metilo sustituido
WO2010068708A3 (en) 3&#39;-azido purine nucleotide prodrugs for treatment of viral infections
PA8590801A1 (es) Derivados de nucleosido antivirales
TH126308A (th) สารประกอบ และองค์ประกอบทางเภสัชกรรมสำหรับการบำบัดการติดเชื้อไวรัส
UY28110A1 (es) Derivados de nucleosido antivirales
GT200300246A (es) Derivados antivirales de nucleosidos
TH126308B (th) สารประกอบ และองค์ประกอบทางเภสัชกรรมสำหรับการบำบัดการติดเชื้อไวรัส
ECSP024381A (es) Agentes antivirales de imidazopiridina e imidazopirimidina

Legal Events

Date Code Title Description
FG Application granted